Tyrosine kinase inhibitors (TKIs) targeting specific driver mutations, including EGFR, ALK, and ROS‐1, are widely used for patients with advanced NSCLC harboring corresponding driver mutations, with manageable toxicities and promising treatment efficacies.24 This evidence concerns the gene ALK and non-small cell lung carcinoma.